Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450

被引:63
作者
Choi, MH
Skipper, PL
Wishnok, JS
Tannenbaum, SR
机构
[1] MIT, Biol Engn Div, Cambridge, MA 02139 USA
[2] MIT, Dept Chem, Cambridge, MA 02139 USA
关键词
D O I
10.1124/dmd.104.003327
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A combination of accelerator mass spectrometry (AMS) and liquid chromatography-tandem mass spectrometry has been used to clarify some new aspects of testosterone metabolism. The main pathway of testosterone oxidative metabolism by human liver microsomes is the formation of 1 beta-, 2 alpha- /beta-, 6 beta-, 15 beta-, and 16 beta-hydroxytestosterones, mainly catalyzed by cytochromes P450 2C9, 2C19, and 3A4. We now report the first determination that 11 beta-hydroxytestosterone ( 11 beta-OHT) can also be formed by human liver microsomal fractions. The structures of five hydroxylated metabolites of testosterone (2 beta-, 6 beta-, 11 beta-, 15 beta-, and 16 beta-OHT) and the C-17 oxidative metabolite androstenedione were determined by liquid chromatography with UV detection at 240 nm and liquid chromatography-tandem mass spectrometry. Corresponding results were obtained by high-performance liquid chromatography-AMS analysis of incubations of [4-C-14] testosterone with human liver microsomes. 6 beta-Hydroxylation was always the dominant metabolic pathway, but 2 beta-, 15 beta-, and 16 beta-OHT, and androstenedione were also formed. The previously undetected hydroxytestosterone, 11 beta-OHT, was found to be a minor metabolite formed by human liver microsomal enzymes. It was formed more readily by CYP3A4 than by either CYP2C9 or CYP2C19. 11 beta-Hydroxylation was inhibited by ketoconazole (IC50 = 30 nM) at concentrations similar to the IC50 (36 nM) for 6 beta-hydroxylation Therefore, CYP3A4 could be mainly responsible for testosterone 11 beta-hydroxylation in the human liver. These findings identify human hepatic biotransformation of testosterone to 11 beta-OHT as a previously unrecognized extra-adrenal metabolic pathway.
引用
收藏
页码:714 / 718
页数:5
相关论文
共 29 条
[1]  
CHANG E, 1963, J BIOL CHEM, V238, P913
[2]   Measurement of corticoids in the patients with clinical features indicative of mineralocorticold excess [J].
Choi, MH ;
Hahm, JR ;
Jung, BH ;
Chung, BC .
CLINICA CHIMICA ACTA, 2002, 320 (1-2) :95-99
[3]   Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes [J].
Eagling, VA ;
Tjia, JF ;
Back, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (02) :107-114
[4]  
EBERLEIN WR, 1956, J BIOL CHEM, V223, P85
[5]  
FEUER G, 1986, CANCER RES, V46, P76
[6]  
Guengerich F. Peter, 1994, P1259
[7]  
HOBKIRK R, 1979, STEROID BIOCH, P164
[8]   IN-VITRO BIOSYNTHESIS OF 11 BETA-HYDROXYANDROSTENEDIONE BY HUMAN ADRENAL HOMOGENATES [J].
HUDSON, RW ;
KILLINGER, DW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1972, 34 (01) :215-+
[9]   PURIFICATION OF HUMAN-LIVER CYTOCHROME-P-450 CATALYZING TESTOSTERONE 6-BETA-HYDROXYLATION [J].
KAWANO, S ;
KAMATAKI, T ;
YASUMORI, T ;
YAMAZOE, Y ;
KATO, R .
JOURNAL OF BIOCHEMISTRY, 1987, 102 (03) :493-501
[10]   BIOGENESIS OF 11BETA-HYDROXYOESTRONE AND 16ALPHA-HYDROXYOESTRONE BY ADRENAL TISSUE [J].
KNUPPEN, R ;
BREUER, H .
BIOCHIMICA ET BIOPHYSICA ACTA, 1962, 58 (01) :147-&